Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Total Non-current Liabilities
All obligations due after more than one year.
Beta Bionics, Inc.NASDAQ: BBNX
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities rises 28.3% from a year ago
Total non-current liabilities stood at $9.98M at the end of Q1 FY2026, up 28.3% from a year earlier and down 2.2% from the prior quarter. Over 3 fiscal years it compounded at -9.2% a year.
Context
- Total non-current liabilities amounted to 3.3% of total assets at the end of Q1 FY2026, up 1.0 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +28.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 10.21M USD
- Year-over-year change
- -80.5%
- 3-year CAGR
- -9.2%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.21M | -80.5% |
| FY2024 | 2024-12-31 | 52.48M | +28.6% |
| FY2023 | 2023-12-31 | 40.83M | +199.0% |
| FY2022 | 2022-12-31 | 13.65M | — |
Total Non-current Liabilities vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +28.3% is the 4th highest of 7, against a peer median of +43.9%.
- Total non-current liabilities amounts to 3.3% of total assets for BBNX, versus a peer median of 22.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | DKK 134.58B DKK | +26.3% | +53.5% | 22.6% | |
| Jun 2026 | $1.48B USD | +2.1% | +0.7% | 22.9% | |
| Jun 2026 | $998.7M USD | +0.3% | -11.0% | 31.6% | |
| Mar 2026 | $773.03M USD | +61.5% | +2.6% | 67.0% | |
| Mar 2026 | $669.04M USD | +89.6% | +12.0% | 89.9% | |
MMEDMiniMed Group, Inc. Common Stock | Jul 2026 | $316M USD | — | — | 6.7% |
| Mar 2026 | $20.01M USD | +829.3% | +36.4% | 7.4% | |
| Mar 2026 | $9.98M USD | +28.3% | -9.2% | 3.3% | |
| Peer median (excluding BBNX) | — | +43.9% | +7.3% | 22.9% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.